Alembic receives FDA nod for generic CorlanorIvabradine is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. Watch DSN: Healthcare collaboration boosts outcomes for GLP-1 patientsAmanda Jochum, a registered dietitian with Hy-Vee, discusses GLP-1 medication side effects, patient support strategies and beneficial product recommendations. NACDS to 118th Congress: Now, let’s get PBM reform done NACDS President Steve Anderson said there remains an urgent need for the current 118th Congress to reform the tactics of market-dominant pharmaceutical middlemen. Camber releases generic Xeloda Capecitabine is a nucleoside metabolic inhibitor indicated for the treatment of several cancers. Hims & Hers Health plans to launch generic of Novo Nordisk's Victoza Liraglutide, used to treat Type 2 diabetes, belongs to the first generation of GLP-1 agonists. FDA gives Lupin tentative nod for generic Isentress Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus infection. Alembic obtains FDA nod for generic Cardizem Generic Cardizem is indicated for the treatment of hypertension and the management of chronic stable angina and angina due to coronary artery spasm. Bora Pharmaceuticals acquires Pyros Pharmaceuticals Pyros is a specialty pharmaceutical company developing treatments for rare diseases. Sandoz launches generic paclitaxel in single-dose vial The single-dose 100 mg vial for intravenous use is approved for metastatic breast cancer. Who's using GLP-1s? Obesity patients earning over $250,000 annually are 72% more likely to take a GLP-1 than those earning $50,000 or less, per a new study. First Previous 4 5 6 7 8 Next Last
